PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Zhenlin YangYue PengWei GuoJiachen XuLin LiHe TianRenda LiLei LiuFengwei TanShugeng GaoJie HePublished in: Thoracic cancer (2021)
PD-L1/CD47 co-expression was an independent prognostic factor for LUSC and LUAD patients and may serve as a potential predictive biomarker for combined dual-targeting immunotherapy.